A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Have Trusted Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 358
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2024 IOL Market Report: Global Analysis for 2023 to 2029, March, 2024
The “2024 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
4/12/2024
BreakingGenericsGlaucomaPharmaRegulation
Leading Generic Drugmakers Sued by Large Employers in Price Fixing Scheme
Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...
4/12/2024
BreakingPharmaRegulationRetina
US Accuses Regeneron of Fraudulent Drug Price Reporting for Eylea
The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. T...
4/12/2024
BreakingDealsIndiaIndustry
US Private Equity Firm Warburg Pincus Buys Controlling Stake in India’s Appasamy
US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...
4/12/2024
BreakingCataractDealsIndustryPharma
Eyenovia Explores Strategic Alternatives as it Rolls Out Mydcombi, Postsurgical Steroid
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
4/12/2024
BreakingEmergingEuropeFundingGlaucomaSurgical
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...
4/12/2024
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Clears IND Amendment with New Mobility Test for Phase III Trial of Ocugen RP Gene Therapy Candidate
Ocugen announced April 8 that the US FDA had cleared the company’s investigational new drug (IND) amendment to initiate a Phase III clinical trial of OCU400, a modifier gene therapy candidate for r...
4/12/2024
BreakingCataractIOLSurgical
Rayner Marks Sale of 5 Millionth RayOne IOL
UK-based Rayner reported April 3 that it had sold its 5 millionth RayOne lens and 11 millionth lens made from RayAcryl, Rayner’s proprietary hydrophilic acrylic material. Rayner, founded in 1910, r...
4/5/2024
BreakingClinical TrialPresbyopia
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative-free, single-use, once-daily ey...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.